GENZYME CORP Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENZYME CORP, and what generic alternatives to GENZYME CORP drugs are available?
GENZYME CORP has three approved drugs.
There are five US patents protecting GENZYME CORP drugs.
There are one hundred and seventy-six patent family members on GENZYME CORP drugs in fifty countries and twenty-three supplementary protection certificates in sixteen countries.
Summary for GENZYME CORP
International Patents: | 176 |
US Patents: | 5 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 3 |
Drug Master File Entries: | 9 |
Patent Litigation for GENZYME CORP: | See patent lawsuits for GENZYME CORP |
Drugs and US Patents for GENZYME CORP
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-002 | Apr 6, 2011 | RX | Yes | Yes | 8,067,427 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | RX | Yes | No | 8,067,427 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | AB | RX | Yes | Yes | 11,458,119 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |
Genzyme Corp | FLUDARA | fludarabine phosphate | INJECTABLE;INJECTION | 020038-001 | Apr 18, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GENZYME CORP
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | 7,173,038 | ⤷ Sign Up |
Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-002 | Apr 6, 2011 | 8,642,608 | ⤷ Sign Up |
Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | 6,916,802 | ⤷ Sign Up |
Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | 6,414,148 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENZYME CORP drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tartrate Capsules | 84mg | ➤ Subscribe | 2018-08-20 |
International Patents for GENZYME CORP Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Argentina | 110045 | ⤷ Sign Up |
Malaysia | 138868 | ⤷ Sign Up |
Spain | 2754398 | ⤷ Sign Up |
Montenegro | 01505 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for GENZYME CORP Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1409467 | 37/2015 | Austria | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
1409467 | 2015/027 | Ireland | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
1409467 | 132016000023075 | Italy | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACOLOGICAMENTE ACCETTABILE(CERDELGA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/974, 20150119 |
1409467 | CR 2015 00035 | Denmark | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, EVENTUELT I FORM AF ET FYSIOLOGISK ACCEPTABELT SALT, HERUNDER ELIGLUSTAT (SOM TARTRAT); REG. NO/DATE: EU/1/14/974 20150119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.